On October 21, Sinopharm Holdings announced that recently, the subsidiary Yunnan Sinopharm Control shareholder Chang Pharmaceutical Co., Ltd. within the scope of the company's merger failed to repay its maturing debt. The amount overdue amount was 28.76 million yuan. The type of debt was a bank loan. According to Sinopharm Holdings, the overdue debt mentioned above is due to account complaints and freezing, and Dongchang of State Control is currently actively communicating and coordinating. The debtor, Guokong Dongchang, involved in the overdue debt mentioned above, is included in the scope of Sinopharm Holdings' consolidated statements. As of the date of issuance of this announcement, Sinopharm Holdings did not provide a debt performance guarantee for Guokong Dongchang. In addition to this, Sinopharm Holdings also stated that Guokong Dongchang is currently unable to pay off maturing debts. Compared with Sinopharm Holdings' overall operating income scale, asset size, etc., the subsidiary's share is relatively low. It is expected that the above related matters will not have a significant adverse impact on the overall solvency of Sinopharm Holdings and the debt service of the current bond.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.